Positive Phase I results for long-acting anti-TL1A antibody
Bionyra Pharma has announced positive interim results from its ongoing Phase I first-in-human study of BYN-002 (TL-001), a long-acting anti-TL1A monoclonal antibody that is in development to treat inflammatory bowel disease (IBD) and other TL1A-driven diseases. The data are being presented in a late-breaking poster at United… Read More